The bisphosphonates: Risks and benefits of long term use

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 435-439

  Hermann, Anne Pernille ^a   Abrahamsen, Bo ^b,c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; PLACEBO; PROTON PUMP INHIBITOR; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CANCER RISK; CHRONIC DRUG ADMINISTRATION; DRUG EFFICACY; DRUG SAFETY; FEMUR FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INTERVENTION STUDY; JAW OSTEONECROSIS; OBSERVATIONAL STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SPINE FRACTURE; TREATMENT DURATION; TREATMENT RESPONSE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84879115259     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.02.002     Document Type: Review

References (27)

1. J.-Y. Reginster Antifracture efficacy of currently available therapies for postmenopausal osteoporosis Drugs 71 2011 65 78
2. M.L. Frost, M. Siddique, G.M. Blake, E. Moore a, P.K. Marsden, P.J. Schleyer, R. Eastell, and I. Fogelman Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women Osteoporos Int 23 2012 2107 2116
3. A. Grey, M.J. Bolland, D. Wattie, A. Horne, G. Gamble, and I.R. Reid The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women J Clin Endocrinol Metab 94 2009 538 544
4. R. Eastell, J.S. Walsh, N.B. Watts, and E. Siris Bisphosphonates for postmenopausal osteoporosis Bone 49 2011 82 88
5. G. Bianchi, E. Czerwinski, A. Kenwright, A. Burdeska, R.R. Recker, and D. Felsenberg Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension Osteoporos Int 23 2012 1769 1778
6. O.H. Sorensen, G.M. Crawford, H. Mulder, D.J. Hosking, C. Gennari, D. Mellstrom, S. Pack, D. Wenderoth, C. Cooper, and J.-Y. Reginster Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 2003 120 126
7. D.M. Black, A.V. Schwartz, K.E. Ensrud, J.A. Cauley, S. Levis, S.A. Quandt, S. Satterfield, R.B. Wallace, D.C. Bauer, and L. Palermo Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial J Am Med Assoc 296 2006 2927 2938
8. D.M. Black, I.R. Reid, S. Boonen, C. Bucci-Rechtweg, J.A. Cauley, F. Cosman, S.R. Cummings, T.F. Hue, K. Lippuner, and P. Lakatos The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res 27 2012 243 254
9. H.G. Bone, D. Hosking, J.P. Devogelaer, J.R. Tucci, R.D. Emkey, R.P. Tonino, J.A. Rodriguez-Portales, R.W. Downs, J. Gupta, and A.C. Santora Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 2004 1189 1199
10. R. Eastell, R.A. Hannon, D. Wenderoth, J. Rodriguez-Moreno, and A. Sawicki Effect of stopping risedronate after long-term treatment on bone turnover J Clin Endocrinol Metab 96 2011 3367 3373
11. L.Y. Park-Wyllie, M.M. Mamdani, D.N. Juurlink, G.A. Hawker, N. Gunraj, P.C. Austin, D.B. Whelan, P.J. Weiler, and A. Laupacis Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women J Am Med Assoc 305 2011 783 789
12. M. Pazianas, B. Abrahamsen, Y. Wang, and R.G.G. Russell Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases Osteoporos Int 23 2012 2873 2884
13. E. Barrett-Connor, A.S. Swern, C.M. Hustad, H.G. Bone, U.A. Liberman, S. Papapoulos, H. Wang, A. De Papp, and A.C. Santora Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials Osteoporos Int 23 2012 233 245
14. A. Grosso, I. Douglas, A. Hingorani, R. MacAllister, and L. Smeeth Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis PLoS ONE 4 2009 e4720
15. B. Abrahamsen, P. Eiken, and K. Brixen Atrial fibrillation in fracture patients treated with oral bisphosphonates J Intern Med 265 2009 581 592
16. K. Sun, J.M. Liu, H.X. Sun, N. Lu, and G. Ning Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies Osteoporos Int 24 2013 279 286
17. M. Pazianas, and R.G.G. Russell Potential therapeutic effects of oral bisphosphonates on the intestine Ann N Y Acad Sci 1240 2011 E19 E25
18. K.E. Fleisher, A. Jolly, U.D.C. Venkata, R.G. Norman, D. Saxena, and R.S. Glickman Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy J Oral Maxillofac Surg 2012 (online)
19. V.M. Cartsos, S. Zhu, and A.I. Zavras Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people J Am Dent Assoc 139 2008 23 30
20. J. Schilcher, K. Michaelsson, and P. Aspenberg Bisphosphonate use and atypical fractures of the femoral shaft N Engl J Med 364 2011 1728 1737
21. J.C. Lo, S.Y. Huang, G.A. Lee, S. Khandewal, J. Provus, B. Ettinger, J.R. Gonzalez, R.L. Hui, and C.D. Grimsrud Clinical correlates of atypical femoral fracture Bone 51 2012 181 184
22. R.M. Dell, A.L. Adams, D.F. Greene, T.T. Funahashi, S.L. Silverman, E.O. Eisemon, H. Zhou, R.J. Burchette, and S.M. Ott Incidence of atypical nontraumatic diaphyseal fractures of the femur J Bone Miner Res 27 2012 2544 2550
23. E. Shane, D. Burr, P.R. Ebeling, B. Abrahamsen, R.A. Adler, T.D. Brown, A.M. Cheung, F. Cosman, J.R. Curtis, and R. Dell Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 25 2010 2267 2294
24. A. Feldstein, D. Black, N. Perrin, A.G. Rosales, D. Friess, D. Boardman, R. Dell, A. Santora, J.M. Chandler, and M.M. Rix Incidence and demography of femur fractures with and without atypical features J Bone Miner Res 27 2012 977 986
25. J. Schilcher, V. Koeppen, J. Ranstam, R. Skripitz, K. Michaëlsson, and P. Aspenberg Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls Bone 52 2013 389 392
26. B. Abrahamsen, P. Eiken, and R. Eastell Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis J Clin Endocrinol Metab 95 2010 5258 5265
27. B. Abrahamsen Atypical femur fractures: refining the clinical picture J Bone Miner Res 27 2012 975 976